BRPI0000126B8 - composição de vacina, composição adjuvante e método de produção de uma composição de vacina - Google Patents

composição de vacina, composição adjuvante e método de produção de uma composição de vacina

Info

Publication number
BRPI0000126B8
BRPI0000126B8 BRPI0000126A BR0000126A BRPI0000126B8 BR PI0000126 B8 BRPI0000126 B8 BR PI0000126B8 BR PI0000126 A BRPI0000126 A BR PI0000126A BR 0000126 A BR0000126 A BR 0000126A BR PI0000126 B8 BRPI0000126 B8 BR PI0000126B8
Authority
BR
Brazil
Prior art keywords
composition
vaccine composition
vaccine
producing
adjuvant
Prior art date
Application number
BRPI0000126A
Other languages
English (en)
Other versions
BRPI0000126B1 (pt
BR0000126A (pt
Inventor
Stewart Roberts David
Alan Dearwester Don
Allen Swearingin Leroy
Original Assignee
Pah Usa 15 Llc
Pfizer Prod Inc
Zoetis P Llc
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pah Usa 15 Llc, Pfizer Prod Inc, Zoetis P Llc, Zoetis Services Llc filed Critical Pah Usa 15 Llc
Priority to BRPI0017566A priority Critical patent/BRPI0017566B1/pt
Publication of BR0000126A publication Critical patent/BR0000126A/pt
Publication of BRPI0000126B1 publication Critical patent/BRPI0000126B1/pt
Publication of BRPI0000126B8 publication Critical patent/BRPI0000126B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

patente de invenção: <b>"adjuvantes para uso em vacinas"<d>. a presente invenção refere-se a adjuvantes que contêm uma lecitina, um óleo e um tensoativo anfifílico e que são capazes de formar uma emulsão de vacina estável de óleo-em-água de forma a minimizar as reações locais à vacina no animal injetado.
BRPI0000126A 1999-01-29 2000-01-19 composição de vacina, composição adjuvante e método de produção de uma composição de vacina BRPI0000126B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0017566A BRPI0017566B1 (pt) 1999-01-29 2000-01-19 composição de antígeno incluindo uma cultura de bordetella bronchiseptica, composição de vacina, método de inativação e vacinas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11770599P 1999-01-29 1999-01-29
US12176099P 1999-02-26 1999-02-26

Publications (3)

Publication Number Publication Date
BR0000126A BR0000126A (pt) 2001-05-02
BRPI0000126B1 BRPI0000126B1 (pt) 2015-07-14
BRPI0000126B8 true BRPI0000126B8 (pt) 2022-05-10

Family

ID=26815550

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0000126A BRPI0000126B8 (pt) 1999-01-29 2000-01-19 composição de vacina, composição adjuvante e método de produção de uma composição de vacina
BRPI0017566A BRPI0017566B1 (pt) 1999-01-29 2000-01-19 composição de antígeno incluindo uma cultura de bordetella bronchiseptica, composição de vacina, método de inativação e vacinas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0017566A BRPI0017566B1 (pt) 1999-01-29 2000-01-19 composição de antígeno incluindo uma cultura de bordetella bronchiseptica, composição de vacina, método de inativação e vacinas

Country Status (17)

Country Link
US (6) US6572861B1 (pt)
EP (2) EP1616573B1 (pt)
JP (3) JP2000219636A (pt)
CN (2) CN1449825B (pt)
AR (2) AR035474A1 (pt)
AT (2) ATE533504T1 (pt)
AU (2) AU769539B2 (pt)
BR (2) BRPI0000126B8 (pt)
CA (2) CA2296244C (pt)
CY (2) CY1105684T1 (pt)
DE (1) DE69928763T2 (pt)
DK (2) DK1023904T3 (pt)
ES (2) ES2251164T3 (pt)
HK (2) HK1030166A1 (pt)
NZ (2) NZ502341A (pt)
PT (1) PT1616573E (pt)
TW (1) TW585777B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6676958B2 (en) * 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
US7279163B1 (en) * 2002-03-21 2007-10-09 The United States Of America, As Represented By The Secretary Of Agriculture Water-in-oil emulsion vaccines
CA2496750C (en) * 2002-08-26 2014-10-21 Pfizer Products Inc. Vaccine for respiratory and reproductive system infections in cattle
JP2006515024A (ja) 2003-01-29 2006-05-18 ファイザー・プロダクツ・インク Ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａに対するイヌワクチン
CN1767854B (zh) * 2003-04-04 2013-07-24 硕腾P有限责任公司 微流化水包油乳剂及疫苗组合物
US8637047B2 (en) * 2003-10-30 2014-01-28 Boehringer Ingelheim Vetmedica, Inc. Erysipelothrix rhusiopathiae-haemophilus parasuis vaccine and methods of using the same
CN1323718C (zh) * 2004-03-15 2007-07-04 中国农业科学院兰州兽医研究所 一种利用植物油佐剂制备动物病毒性、细菌性疫苗的方法
FR2878746B1 (fr) * 2004-12-02 2007-02-23 Vetoquinol Sa Sa Nouvelle composition pharmaceutique utilisable dans le domaine des vaccins
CN1320924C (zh) * 2005-01-07 2007-06-13 邢为藩 一种自乳化疫苗佐剂及其制备方法
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
SI2068918T1 (sl) 2006-09-26 2012-09-28 Infectious Disease Res Inst Si - ep sestavek za cepljenje, ki vsebuje sintetiäśna pomagala
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2673823T3 (es) * 2006-11-03 2018-06-25 Alphavax, Inc. Formulaciones de alfavirus y de partículas de replicones de alfavirus y métodos relacionados
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
CN101827613A (zh) * 2007-09-27 2010-09-08 免疫疫苗技术有限公司 在包括连续疏水相的载体中的脂质体在体内输送多核苷酸中的应用
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
CN101428145B (zh) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 新型疫苗佐剂
CA2723918C (en) * 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
ES2728949T3 (es) 2008-06-27 2019-10-29 Zoetis Services Llc Composiciones adyuvantes novedosas
CN102333540B (zh) 2008-10-06 2015-04-22 芝加哥大学 与细菌eap、emp和/或adsa蛋白相关的组合物和方法
AU2010271116B2 (en) 2009-04-03 2015-08-13 University Of Chicago Compositions and methods related to Protein A (SpA) variants
PT2437753T (pt) 2009-06-05 2016-11-23 Infectious Disease Res Inst Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
US9849174B2 (en) 2009-11-20 2017-12-26 The Board Of Regents Of The University Of Texas System Methods and compositions related to immunogenic fibrils
WO2011063264A1 (en) 2009-11-20 2011-05-26 University Of Chicago Methods and compositions related to immunogenic fibrils
US10080799B2 (en) 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
KR20130048208A (ko) 2010-03-11 2013-05-09 이뮨 디자인 코포레이션 인플루엔자 백신
US8808699B2 (en) 2010-04-05 2014-08-19 The University Of Chicago Compositions and methods related to protein A (SpA) antibodies as an enhancer of immune response
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
WO2011134668A1 (en) 2010-04-30 2011-11-03 Telormedix Sa Phospholipid drug analogs
EP2563401A1 (en) 2010-04-30 2013-03-06 Telormedix SA Methods for inducing an immune response
ES2655701T3 (es) 2010-07-02 2018-02-21 The University Of Chicago Composiciones y métodos relacionados con variantes de la proteína A (SpA)
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US9381241B2 (en) * 2010-09-28 2016-07-05 Kyoritsu Seiyaku Corporation Mucosal adjuvant composition
MX350795B (es) 2011-04-08 2017-09-19 Inmune Design Corp Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
US20120288515A1 (en) 2011-04-27 2012-11-15 Immune Design Corp. Synthetic long peptide (slp)-based vaccines
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2763698B1 (en) 2011-10-06 2020-12-02 ImmunoVaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
GB201205237D0 (en) 2012-03-26 2012-05-09 Univ Edinburgh Adjuvant
ES2806945T3 (es) 2012-04-26 2021-02-19 Univ Chicago Antígenos de coagulasa estafilocócica y métodos para su uso
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
HUE059179T2 (hu) 2012-09-10 2022-10-28 Galenbio Inc Vízimadárban Mycoplasma-fertõzés megelõzésére szolgáló oltóanyag
AU2013327241A1 (en) 2012-10-01 2015-02-26 Urogen Pharma Ltd. Phospholipid drug analogs
JP6426706B2 (ja) 2013-04-18 2018-11-21 イミューン デザイン コーポレイション がん処置で使用するためのｇｌａ単剤療法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
PL3166634T3 (pl) 2014-07-11 2021-12-27 Zoetis Services Llc Nowe kompozycje szczepionek przeciwko wirusowi biegunki epidemicznej świń
WO2016138421A1 (en) 2015-02-27 2016-09-01 Iowa State University Research Foundation, Inc. Porcine epidemic diarrhea virus strains and immunogenic compositions therefrom
CA3010977A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
BR112018069371A2 (pt) 2016-03-21 2019-01-22 South Dakota Board Of Regents construção de ácido nucleico, vetor, vacina ou composição imunogênica, método de entrega de uma vacina, método de produção de uma construção de ácido nucleico e método para conferir imunidade contra um antígeno
WO2017173398A1 (en) 2016-04-01 2017-10-05 Duke University Alpha-helical peptide nanofibers as a self-adjuvanting vaccine platform
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
CN107027749B (zh) * 2017-05-24 2021-04-09 浙江工业大学 一种复合乳化剂及其在复配毒死蜱农药中的应用
ES2705378A1 (es) * 2017-09-22 2019-03-22 Decco Worldwide Post Harvest Holdings B V Metodo para el tratamiento y control de fisiopatias de postcosecha de frutas mediante recubrimientos comestibles.
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
US20210340185A1 (en) 2018-08-29 2021-11-04 Centre Hospitalier Universitaire Vaudois Ebola vaccine compositions and methods of using same
US11208167B2 (en) 2018-11-15 2021-12-28 Kuat Innovations Llc Bicycle rack with actuated arm
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
TW202327646A (zh) 2021-10-15 2023-07-16 美商輝瑞大藥廠 Rna分子
CN113907044A (zh) * 2021-11-09 2022-01-11 福建省连江县刘氏兔业养殖场 一种抗病猪品系的培育方法及其应用
WO2023111907A1 (en) 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023144779A1 (en) 2022-01-28 2023-08-03 Pfizer Inc. Coronavirus antigen variants
WO2024089633A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
AT350181B (de) * 1977-05-04 1979-05-10 Schuller Walter Dr Verfahren zur herstellung einer mischvaccine
US4137115A (en) * 1977-11-07 1979-01-30 Patrick Lambert Joining structure
US4237115A (en) * 1977-11-23 1980-12-02 Bactex, Inc. Method of immunization against enterotoxogenic infection by Escherichia coli
US4261925A (en) 1978-04-05 1981-04-14 The Dow Chemical Company Surfactants
US4504275A (en) 1983-03-24 1985-03-12 Imperial Chemical Industries Plc Emulsifying agents
US4933179A (en) 1983-08-22 1990-06-12 Syntex (U.S.A.) Inc. Feline leukemia virus antigen vaccines
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5338748A (en) 1985-01-18 1994-08-16 Cetylite Industries, Inc. Sterilant composition
US5424323A (en) * 1985-01-18 1995-06-13 Cetylite Industries, Inc. Sterilant composition
DE3517805A1 (de) * 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Impfstoff zur immunisierung von schweinen gegen rhinitis atrophicans (schnueffelkrankheit)
US4803070A (en) * 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4789544A (en) 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5019388A (en) * 1986-10-14 1991-05-28 Norden Laboratories Inc. Bordetella bronchiseptica vaccine
US4888169A (en) 1986-10-14 1989-12-19 Norden Laboratories, Inc. Bordetella Bronchiseptica vaccine
US5084269A (en) * 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US5209929A (en) * 1987-03-19 1993-05-11 Washington State University Research Foundation Immunization against Babesiosis using purified merozoite surface antigens of Basesia bigemina
US5376369A (en) 1987-11-03 1994-12-27 Syntex (U.S.A.) Inc. Vaccine adjuvant
US5069901A (en) * 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
CY1935A (en) * 1990-02-12 1991-02-07 Smithkline Beecham Biolog Novel vaccine and method therefor
CA2082155C (en) * 1990-05-29 2008-04-15 Krishnaswamy I. Dayalu Swine pneumonia vaccine and method of preparation
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
AU8195391A (en) 1990-06-13 1992-01-07 Smithkline Beecham Corporation Pasteurella multocida toxoid vaccines
US5242686A (en) * 1990-11-07 1993-09-07 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
JP3043809B2 (ja) 1991-11-15 2000-05-22 ファイザー・インコーポレイテッド グラム陰性菌ワクチン
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
DE4222153C2 (de) 1992-07-06 1998-12-03 Peter Siegfried Verfahren zur Entölung von Rohlecithin
DK0626452T3 (da) * 1993-05-17 2000-02-14 Akzo Nobel Nv Vaccine mod infektion af Streptococcus suis
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE69528450T2 (de) 1994-02-18 2003-01-23 Solidose L L C Impfung von tieren mit getrockneten pelletierten biologischen materialien
GB2289279B (en) 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
ATE248603T1 (de) * 1994-06-10 2003-09-15 Chemo Sero Therapeut Res Inst Reinigungsverfahren für von bordetella produziertem nekrotoxin
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5625038A (en) * 1994-07-27 1997-04-29 Henderson; Louise M. Monoclonal antibodies specific for Erysipelothrix rhusiopathiae
US5603951A (en) 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
ES2277339T3 (es) * 1995-11-30 2007-07-01 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vacuna con adyuvante de aceite y metodo para su preparacion.
ATE199022T1 (de) 1996-10-09 2001-02-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
ZA982870B (en) * 1997-04-10 1998-10-09 Akzo Nobel Nv Live attenuated bacteria of the species actinobacillus pleuropneumoniae
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
AU769539B2 (en) * 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae

Also Published As

Publication number Publication date
JP2005041883A (ja) 2005-02-17
TW585777B (en) 2004-05-01
US20030175298A1 (en) 2003-09-18
AR055422A2 (es) 2007-08-22
EP1616573A2 (en) 2006-01-18
EP1616573A3 (en) 2007-05-09
JP4785365B2 (ja) 2011-10-05
ATE311900T1 (de) 2005-12-15
AU769539B2 (en) 2004-01-29
PT1616573E (pt) 2012-01-11
CN1270838A (zh) 2000-10-25
US7393535B2 (en) 2008-07-01
HK1030166A1 (en) 2001-04-27
CY1105684T1 (el) 2010-12-22
CA2455134A1 (en) 2000-07-29
CY1112521T1 (el) 2015-12-09
JP5167469B2 (ja) 2013-03-21
ES2251164T3 (es) 2006-04-16
EP1616573B1 (en) 2011-11-16
EP1023904A3 (en) 2002-08-21
AU2004201021A1 (en) 2004-04-08
BRPI0017566B1 (pt) 2015-11-10
US20030175299A1 (en) 2003-09-18
ES2374628T3 (es) 2012-02-20
JP2004002479A (ja) 2004-01-08
DE69928763D1 (de) 2006-01-12
DK1616573T3 (da) 2012-01-30
BRPI0000126B1 (pt) 2015-07-14
US6733754B2 (en) 2004-05-11
EP1023904B1 (en) 2005-12-07
ATE533504T1 (de) 2011-12-15
DE69928763T2 (de) 2006-06-29
US20030175309A1 (en) 2003-09-18
DK1023904T3 (da) 2005-12-27
CA2296244A1 (en) 2000-07-29
US20050058667A1 (en) 2005-03-17
CA2296244C (en) 2004-04-27
EP1023904A2 (en) 2000-08-02
CN1126568C (zh) 2003-11-05
BR0000126A (pt) 2001-05-02
AR035474A1 (es) 2004-06-02
CN1449825A (zh) 2003-10-22
CA2455134C (en) 2010-05-11
AU6537299A (en) 2000-08-03
US6814971B2 (en) 2004-11-09
HK1059739A1 (en) 2004-07-16
NZ502341A (en) 2001-08-31
CN1449825B (zh) 2012-08-22
US20030175308A1 (en) 2003-09-18
NZ513202A (en) 2003-02-28
JP2000219636A (ja) 2000-08-08
US6572861B1 (en) 2003-06-03

Similar Documents

Publication Publication Date Title
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
ES2182850T3 (es) Procedimientos y composiciones para la microencapsulacion de adyuvantes.
CY1118521T1 (el) Συνθεση εμβολιου και μεθοδος χρησης αυτου
BR9007501A (pt) Emulsoes injetaveis multifasicas de tipo a/o/a,adjuvantes oleosos,e,processo para a preparacao e composicoes injetaveis
BRPI0111016B8 (pt) microemulsão água em óleo estavel, biologicamente compatível, bem tolerada e uso da mesma
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
AR053360A1 (es) Formulaciones novedosas de vacunas
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
BR9510223A (pt) Adjuvante para vacinas utilização de um polissacarideo lipidico processo para preparar uma cacina em emulsão e vacina
EA200900350A1 (ru) Вакцина, содержащая адъювант в виде эмульсии &#34;масло в воде&#34;
ES2585810T3 (es) Uso de un virus de la gripe y un adyuvante de emulsión de aceite en agua para inducir respuesta de células T CD4 y/o una respuesta de células B de memoria mejorada
EP2269644A3 (en) Microfluidized oil-in-water emulsions and vaccine compositions
CO4940401A1 (es) Vacunas
UA49814C2 (uk) Композиція, яка містить антиген вірусу папіломи, спосіб лікування цервікального раку, спосіб лікування гострокінцевої кондиломи
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
DE60103735D1 (de) Hautbraünungsmittel
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
ATE298233T1 (de) Kosmetische und pharmazeutische öl-in-wasser- emulsionen von polyethermodifizierten polysiloxanen
NO981944L (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
BRPI0510430A (pt) composições e métodos para vacinação mucosal
FR2814958B1 (fr) Composition vaccinale
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
CL2008003002A1 (es) Composición farmacéutica inyectable intravenosa en forma de emulsión aceite en agua que comprende al toxoide larotaxel (xrp9881) o cabazitaxel (xrp6258) disuelto en lecitina, y al tensioactivo aniónico fosfatidilglicerol o acido fosfatidico; proeceidimiento para su preparacion, útil como antineoplástico.
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE: A61K 9/07, A61K 39/102, A61K 31/04.

Ipc: A61K 39/10 (2010.01), A61K 39/102 (2010.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: PAH USA 15 LLC (US)

B25D Requested change of name of applicant approved

Owner name: ZOETIS P LLC (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/07/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B25G Requested change of headquarter approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/01/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 19/01/2020

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2323, DE 14/07/2015. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 14/07/2015, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.